Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 | Q9ULD8 | 16/20 | 0.86 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1280999 | 0.93 | KCNH3 (1.00) | KCNH3 | |
| SCHEMBL535908 | 0.89 | KCNH3 (1.00) | KCNH3 | |
| SCHEMBL1282182 | 0.83 | KCNH3 (1.00) | KCNH3MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1923771 | 0.79 | KCNH3 (0.82) | KCNH3MAPK1KDM4E | |
| SCHEMBL536016 | 0.78 | KCNH3 (0.49) | KCNH3SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL536394 | 0.77 | KCNH3 (0.52) | KCNH3MAPK1SMN1; SMN2 | |
| SCHEMBL1924158 | 0.77 | KCNH3 (0.71) | KCNH3 | |
| SCHEMBL28229877 | 0.74 | SMN1; SMN2 (0.58) | KCNH3SMN1; SMN2KDM4EALDH1A1BLM | |
| SCHEMBL1923563 | 0.72 | KCNH3 (0.97) | KCNH3 | |
| SCHEMBL1923875 | 0.71 | KCNH3 (0.71) | KCNH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399663-B2 | Salt of 1,3,5-triazine-2,4,6-triamine derivative | ASTELLAS PHARMA INC. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-8399663-B2 | Salt of 1,3,5-triazine-2,4,6-triamine derivative | ASTELLAS PHARMA INC. (JP) | 2013-03-19 | — | — | US | disclosed |
| EP-2413940-A1 | COMPOSITIONS COMPRISING 2, 4, 6-TRIAMINO-1, 3, 5-TRIAZINE DERIVATIVES FOR TREATMENT OF SCHIZOPHRENIA | Astellas Pharma Inc. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20100256151-A1 | NOVEL SALT OF 1,3,5-TRIAZINE-2,4,6-TRIAMINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256151-A1 | NOVEL SALT OF 1,3,5-TRIAZINE-2,4,6-TRIAMINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| WO-2010114163-A1 | COMPOSITIONS COMPRISING 2, 4, 6-TRIAMINO-1, 3, 5-TRIAZINE DERIVATIVES FOR TREATMENT OF SCHIZOPHRENIA | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256151-A1 | NOVEL SALT OF 1,3,5-TRIAZINE-2,4,6-TRIAMINE DERIVATIVE | FH, FAH, GOT1 | KCNH3 2436/4885MAPK1 1458/4885SMN1; SMN2 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.